Develops pemvidutide, an investigational therapy for serious liver diseases, for patients with MASH, alcohol use disorder and alcohol-associated liver disease.
10-K for FY2025, filed Mar 6, 2026
$41K
10-K for FY2025, filed Mar 6, 2026
$41K ↗No. It lost $88.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$31.6MView ↗
8-K, filed Jul 28, 2026
The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week (HDD) versus placebo…View ↗
Shrinking. Revenue fell 99% in 4 years, from $4.4M in FY2021 to $41K in FY2025, about 69% a year.
Focus on liver diseases
The older report described pemvidutide for obesity and non-alcoholic steatohepatitis and also listed a hepatitis B candidate. The latest report focuses on pemvidutide for MASH, alcohol use disorder and alcohol-associated liver disease.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 6, 2026Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our lead…View ↗
Competes with Eli Lilly, Roche, Novo Nordisk, Pfizer, AstraZeneca, Amgen, Boehringer Ingelheim, Merck, Madrigal Pharmaceuticals, Aligos, Viking Therapeutics, GSK, Merck/Hanmi Pharmaceutical, Inventiva, Sagimet, Apollo Therapeutics Group Limited/HEC Pharma, Gilead, Alkermes, Adial, and Imbrium
10-K for FY2025, filed Mar 6, 2026Large and established companies such as Eli Lilly, Roche, Novo Nordisk, Pfizer, AstraZeneca, Amgen, Boehringer Ingelheim and Merck, among…View ↗
Loading...